Abstract:Natural killer (NK) cells destroy tissue that have been opsonized with antibodies. Strategies to generate or identify cells with increased potency are expected to enhance NK cell-based immunotherapies. We previously generated NK cells with increased antibody-dependent cell mediated cytotoxicity (ADCC) following treatment with kifunensine, an inhibitor targeting mannosidases early in the N -glycan processing pathway. Kifunensine treatment also increased the antibody-binding affinity of Fc γ receptor IIIa/CD16a. Here we demonstrate that inhibiting NK cell N -glycan processing increased ADCC. We reduced N -glycan processing with the CRIPSR-CAS9 knockdown of MGAT1, another early-stage N -glycan processing enzyme, and showed that these cells likewise increased antibody binding affinity and ADCC. These experiments led to the observation that NK cells with diminished N -glycan processing capability also revealed a clear phenotype in flow cytometry experiments using the B73.1 and 3G8 antibodies binding two distinct CD16a epitopes. We evaluated this "affinity profiling" approach using primary NK cells and identified a distinct shift and differentiated populations by flow cytometry that correlated with increased ADCC.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to enhance antibody - dependent cell - mediated cytotoxicity (ADCC) by changing the N - glycosylation of CD16a receptor on the surface of natural killer cells (NK cells). Specifically, the researchers focus on how to improve the binding affinity of NK cells to IgG antibodies by inhibiting specific enzymes in the N - glycosylation process (such as using kifunensine or knocking out MGAT1 with CRISPR - Cas9), thereby enhancing their ADCC activity. In addition, they have also developed a flow cytometry - based method, namely "affinity profiling", to distinguish NK cell populations with different affinities, which helps to identify NK cells with higher ADCC potential. The paper mentions that through this affinity profiling method, the differences in IgG binding characteristics between treated NK cells (such as those treated with kifunensine) and untreated NK cells can be observed, and these differences are related to the increase in ADCC activity. This finding is of great significance for optimizing NK cell therapies, especially for improving their effectiveness in cancer treatment.

Distinct CD16a features on human NK cells observed by flow cytometry correlate with increased ADCC